Breast & Women's Cancer | Virtual Congress

Disease Education

Disease Education MOA Resources Clinical Trials

.atomic-select.jsAtomicSelect { display: none; }

Disease Education

Disease Education MOA Resources Clinical Trials

Reimagining Medicine for Patients With Breast & Women's Cancer

More Than Just Words

More Than Just Words is a multiyear initiative in the US to drive toward health equity in breast cancer where there is an unmet need.

Learn More

The Treatment Gap in eBC

There is an urgent unmet medical need in early breast cancer (eBC). Learn about the unacceptable risk of recurrence and the limitations of currently available treatments to address the needs of patients with stage II & III HR+/HER2- eBC.

Learn More

The Risk of Recurrence in HR+/HER2- Early Breast Cancer

Patients with HR+/HER2– early breast cancer carry a substantial risk of recurrence even with currently approved therapies.

Reimagining Medicine for Patients With Breast & Women's Cancer

Ribociclib Proposed Mechanism of Action in HR+/HER2− Early Breast Cancer

Investigational ribociclib is a CDK4/6 inhibitor with preferential selectivity for CDK4.

Intrinsic Subtypes in HR+/HER2-

Learn more about the prognostic and predictive value of intrinsic subtypes in HR+/HER2- advanced breast cancer and the capacity of these subtypes to subtype switch.

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

MOA data are based on in vitro/in vivo data.

aBC = advanced breast cancer; HER2- = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; HR+ = hormone receptor positive; PI3K = phosphoinositol 3 kinase; TNBC = triple-negative breast cancer.